Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine …
M Sheng, F Wang, Y Zhao, S Li, X Wang… - European journal of …, 2016 - Springer
Purpose Exon 19 deletion and exon 21 L858R mutation were the most common epidermal
growth factor receptor (EGFR) mutations. We examined the clinical impact of these two …
growth factor receptor (EGFR) mutations. We examined the clinical impact of these two …
[引用][C] Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after …
M Sheng, F Wang, Y Zhao, S Li, X Wang… - European Journal of …, 2015 - cir.nii.ac.jp
Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring
epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors …
epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors …
Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine …
M Sheng, F Wang, Y Zhao, S Li, X Wang… - European Journal of …, 2016 - infona.pl
Purpose Exon 19 deletion and exon 21 L858R mutation were the most common epidermal
growth factor receptor (EGFR) mutations. We examined the clinical impact of these two …
growth factor receptor (EGFR) mutations. We examined the clinical impact of these two …
Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine …
M Sheng, F Wang, Y Zhao, S Li, X Wang… - … Journal of Clinical …, 2016 - search.proquest.com
Purpose Exon 19 deletion and exon 21 L858R mutation were the most common epidermal
growth factor receptor (EGFR) mutations. We examined the clinical impact of these two …
growth factor receptor (EGFR) mutations. We examined the clinical impact of these two …
Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine …
M Sheng, F Wang, Y Zhao, S Li… - … Journal of Clinical …, 2016 - search.ebscohost.com
Purpose: Exon 19 deletion and exon 21 L858R mutation were the most common epidermal
growth factor receptor (EGFR) mutations. We examined the clinical impact of these two …
growth factor receptor (EGFR) mutations. We examined the clinical impact of these two …
Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine …
M Sheng, F Wang, Y Zhao, S Li… - … journal of clinical …, 2016 - pubmed.ncbi.nlm.nih.gov
Purpose Exon 19 deletion and exon 21 L858R mutation were the most common epidermal
growth factor receptor (EGFR) mutations. We examined the clinical impact of these two …
growth factor receptor (EGFR) mutations. We examined the clinical impact of these two …
Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine …
M Sheng, F Wang, Y Zhao, S Li, X Wang… - European Journal of …, 2016 - europepmc.org
Purpose Exon 19 deletion and exon 21 L858R mutation were the most common epidermal
growth factor receptor (EGFR) mutations. We examined the clinical impact of these two …
growth factor receptor (EGFR) mutations. We examined the clinical impact of these two …